je.st
news
Tag: merck
Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
2015-04-23 09:30:00| Merck.com - Research & Development News
Dateline City: VIENNA C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Nave and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER, the companys Phase 2/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1).1 Treatment-nave patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
advanced
study
Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
2015-04-22 14:00:22| Merck.com - Corporate News
Dateline City: Kenilworth, NJ Platinum-Recording Artist and Actor Rallies People to Make a Pledge with Americas Diabetes Challenge: Get to Your Goals Program KENILWORTH, N.J., April 22, 2015 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control. Language: English read more
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
2015-04-21 14:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-295-0928orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: treatment
continued
annual
developing
Merck aims to quickly repay loans for Sigma-Aldrich acquisition
2015-04-20 15:00:39| Chemicals - Topix.net
German pharmaceutical and chemical firm Merck plans to quickly repay up to $5 billion in loans it used to finance its purchase of Sigma-Aldrich in order to prepare for further acquisitions. Marcus Kuhnert , Merck's finance chief, told the Boersen-Zeitung newspaper that the company wants to reduce the loans "very aggressively within two to three years," Reuters reports.
Tags: quickly
loans
acquisition
aims
Merck aims to quickly repay loans for Sigma-Aldrich acquisition
2015-04-20 15:00:38| Chemicals - Topix.net
German pharmaceutical and chemical firm Merck plans to quickly repay up to $5 billion in loans it used to finance its purchase of Sigma-Aldrich in order to prepare for further acquisitions.
Tags: quickly
loans
acquisition
aims
Sites : [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] next »